Sanofi inks $1.8B licensing deal to boost autoimmune drug pipeline

French pharmaceutical company Sanofi agreed to pay up to $1.8 billion in an exclusive licensing deal with an under-the-radar biotech Earendil Labs.

Why it matters: It's the third autoimmune deal in recent weeks for Sanofi, which is looking to become an immunology powerhouse.